| Website | lycera.com |
| Category | BioTech |
| Employees | |
| Description | Pharm. for abnormal cell growth |
| TOTAL | $36M |
| FUNDING TOTAL | $36M |
| Series A, 5/09 InterWest Partners ARCH Venture Partners Clarus Ventures EDF Ventures | $36M |
Lycera isa preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosis and inflammatory bowel disease Lycera’s first-in-class drugs are designed to treat immune disorders. Lycera’s technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway.
Drugs that emerge from the Lycera pipeline will represent first-in-class agents that have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents.
